Lexington-based Transposagen Biopharmaceuticals, which creates genetically modified laboratory rats, said Thursday that it has expanded its licensing agreement to use certain technology. The technology in question is called PiggyBac and is the core technology used to create Transposagen's line of laboratory rats that mimic human disease and assist in drug development.
The technology is jointly owned by the University of Notre Dame, the University of Florida and the U.S. Department of Agriculture. Under the expanded licensing deal, Transposagen will begin using PiggyBac to "modify the genomes of other important organisms," Transposagen chief executive Dr. Eric Ostertag said in a news release. Transposagen will be responsible for distributing the technology to researchers at universities and non-profits, as well as to pharmaceutical companies for drug development.